Welcome to our dedicated page for Biorestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on Biorestorative Therapies stock.
BioRestorative Therapies Inc (BRTX) is a pioneering biotechnology company advancing autologous stem cell therapies for chronic disc/spine conditions and metabolic disorders. This dedicated news hub provides investors and industry professionals with essential updates on clinical developments, regulatory milestones, and corporate announcements.
Access timely information about BRTX-100 clinical trials, metabolic program research, financial disclosures, and strategic partnerships. Our curated collection ensures transparent tracking of progress in regenerative medicine, featuring official press releases and verified news coverage.
Key focus areas include FDA communications, peer-reviewed study results, intellectual property developments, and executive leadership updates. Users benefit from centralized access to critical information for informed decision-making without promotional bias.
Bookmark this page for ongoing updates on BioRestorative Therapies' innovative work in cell-based medical solutions. Check regularly for new developments in non-surgical treatment alternatives and metabolic health innovations.
BioRestorative Therapies (NASDAQ: BRTX) announced an upcoming interview with CEO Lance Alstodt on Famela and Friends Talk Radio, focusing on the company's clinical development pipeline. BioRestorative is currently conducting a Phase 2 trial for its lead therapy candidate, BRTX-100, aimed at treating chronic lumbar disc disease. The trial involves up to 99 patients across 15 U.S. centers, assessing safety and efficacy. The company also highlighted its Metabolic Program utilizing stem cells from brown adipose tissue.
BioRestorative Therapies (NASDAQ: BRTX) announced CEO Lance Alstodt will present at the Dawson James Securities 7th Annual Small Cap Growth Conference on October 12, 2022, in Jupiter, Florida. The presentation will cover the company's Phase 2 clinical trial using BRTX-100, aimed at treating chronic lumbar disc disease. This double-blind trial will involve up to 99 patients at 15 sites in the U.S., comparing the investigational drug to a control group.
For live webcasts and details, visit BioRestorative's website.
BioRestorative Therapies (NASDAQ: BRTX) announced that CEO Lance Alstodt will speak at the Roth Inaugural Healthcare Opportunities Conference on October 6, 2022, in New York City. He will provide updates on the Phase 2 clinical trial of BRTX-100, a stem cell therapy aimed at treating chronic lumbar disc disease. The trial involves up to 99 patients across 15 sites, comparing the investigational treatment against a control.
Meetings with management can be arranged through Roth representatives.
BioRestorative Therapies (BRTX) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. CEO Lance Alstodt will provide updates on the company's expanded pipeline, specifically the Phase 2 clinical trial targeting chronic lumbar disc disease. The presentation is scheduled for September 14, 2022, at 11:30 AM EDT. BioRestorative focuses on cell-based therapies for disc disorders and metabolic conditions, including its lead candidate BRTX-100, aimed at non-surgical treatment for lower back pain.
BioRestorative Therapies (NASDAQ: BRTX) has achieved a significant milestone by enrolling the first patient in its Phase 2 clinical trial for BRTX-100, aimed at addressing chronic lumbar disc disease (cLDD). This double-blind, controlled study will involve up to 99 patients across 15 U.S. sites. CEO Lance Alstodt emphasized the importance of this enrollment, highlighting a commitment to advancing treatment options for back pain and ensuring timely execution of their clinical programs. The trial may represent a paradigm shift in the treatment of chronic back pain.
BioRestorative Therapies (NASDAQ: BRTX) has secured a second clinical site for its Phase 2 trial targeting chronic lumbar disc disease (cLDD). This trial will evaluate the safety and preliminary efficacy of BRTX-100, an autologous stem cell-based therapy, through a randomized double-blind study involving up to 99 patients across 15 sites in the U.S. The principal investigator, Dr. Richard Rauck, will lead the trial at the Center for Clinical Research in North Carolina, enhancing the clinical expertise essential for the trial's success.
BioRestorative Therapies (NASDAQ: BRTX) has initiated site preparation for its Phase 2 clinical trial targeting chronic lumbar disc disease (cLDD). The Denver Spine and Pain Institute is the first site ready to enroll patients. The trial will assess the safety and preliminary efficacy of a single intradiscal injection of the investigational stem cell therapy BRTX-100, involving up to 99 patients across 15 centers in a randomized, controlled study. There are currently no approved cell-based therapies for cLDD, and positive trial outcomes could disrupt existing treatment paradigms.
BioRestorative Therapies (NASDAQ: BRTX) announced a Principal Investigators Meeting on April 29-30, 2022, in Uniondale, NY, for their lead clinical candidate BRTX-100 aimed at treating chronic lumbar disc disease. This Phase 2 trial plans to recruit 99 subjects across 15 clinical sites in the U.S. The company aims to coordinate study goals among principal investigators to ensure best practices. Low back pain affects 80% of adults in the U.S., representing a significant healthcare burden.
BioRestorative Therapies (NASDAQ: BRTX) has chosen 10 clinical sites for its Phase 2 trial targeting chronic lumbar disc disease. This double-blind, randomized study aims to evaluate the safety and preliminary efficacy of the investigational drug BRTX-100 through a single intradiscal injection. A total of up to 99 eligible patients will be randomized across 15 centers. The selection of high-caliber clinics is highlighted as a significant milestone, indicating BioRestorative's commitment to enhancing treatment options for patients suffering from this condition.
BioRestorative Therapies has completed certification of its clinical grade cell therapy manufacturing facility in Melville, NY, which meets FDA and EMA standards. This facility supports the ongoing Phase 2 trial of BRTX-100, targeting chronic lumbar disc disease. The trial includes up to 99 patients across 15 sites and is set to begin patient treatment in Q2 2022. The facility enhances quality control for BRTX-100 production, critical for the upcoming clinical trial. BioRestorative's focus remains on developing therapies using adult stem cells.
